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When enough is enough
Steffen Foss Hansen and Anders Baun
The European Commission should be regulating nanosilver, not asking for yet another report on its 
impact on health and the environment.
In December 2011 the European Commission asked its Scientific Committee on Emerging and Newly 
Identified Health Risks (SCENIHR) to 
provide a scientific opinion on nanosilver1. 
Specifically, this committee, which consists 
of independent scientists appointed 
by the Commission, is being asked to 
answer four questions under the general 
heading of ‘Nanosilver: safety, health 
and environmental effects, and role in 
antimicrobial resistance’. However, most 
of these questions (and possibly all of 
them) have already been addressed by no 
less than 18 review articles in scientific 
journals, the oldest dating back to 20082–4, 
plus at least seven more reviews and 
reports commissioned and/or funded 
by governments and other organizations 
(Table 1). This raises an important question: 
when will governments and regulatory 
agencies stop asking for more reports and 
reviews, and start taking regulatory action?
In 2008, Sam Luoma (University of 
California, Davis) opened what now seems 
to be Pandora’s silver box with his excellent 
overview of nanosilver and the environment3. 
In 2009, six reviews were published on this 
topic5–10, including reports commissioned 
by the Department of Environment, Food 
and Rural Affairs (DEFRA) in the UK6, the 
Federal Ministry of Food, Agriculture and 
Consumer Protection (BfR) in Germany7 
and the National Institute for Public Health 
and the Environment (RIVM) in the 
Netherlands8. One of the two vice-chairs 
of SCENIHR, Wim De Jong (RIVM), also 
co-authored a review article in the journal 
Nanotoxicology that is now one of the most 
cited papers in the field10.
A further eight review articles in 
scientific journals followed in 201011–18, plus 
substantial reports commissioned by the 
Environmental Protection Agency (EPA) 
in the US (which ran to 221 pages)19 and 
the Joint Research Centre (JRC) of the 
European Commission (426 pages)20. Two 
of the review articles in journals were also 
funded by the European Commission14,16. 
And 2011 saw the publication of five more 
review articles on nanosilver in scientific 
journals21–25, plus a 136-page report from the 
Danish Environmental Protection Agency 
(Danish EPA) about nanosilver and six other 
nanomaterials26.
Many of these reviews and reports go 
through the same literature, cover the same 
ground and identify many of the same data 
gaps and research needs. Hence, we predict 
that the SCENIHR’s upcoming review will 
consist of five main sections summarizing: 
the properties and uses of nanosilver; human 
and environmental toxicity; microbial 
resistance; risk assessment; and research 
needs3,8,10,14,16,18–20,24–26. We also predict that the 
SCENIHR’s report will say something along 
the following lines: “Nanosilver is reportedly 
one of the most widely used nanomaterials 
in consumer products today but the scale 
of production and use is unknown. The 
antibacterial properties of nanosilver are 
exploited in a very diverse set of products and 
applications including dietary supplements, 
personal care products, powdered colours, 
textile, paper, kitchenware and food storage.” 
And like many previous reviews and 
reports3,10,14,18–21,25,26, the new report is likely 
to cite the Consumer Product Inventory 
maintained by the Project on Emerging 
Nanotechnologies27.
After reviewing the literature on human 
toxicity, there is a good chance that the 
SCENIHR will say that the toxicity of silver 
metal is generally considered to be relatively 
low, while noting that a non-life-threatening 
bluish–grey discolouring of the skin has been 
found only after high and repeated ingestion 
or inhalation of colloidal silver2,3,10,20,21,24,26. 
And the conclusions will probably echo 
those of the highly cited review published 
in Nanotoxicology in 2009 and several other 
recent reviews6,14,20,23 by saying something 
along the following lines: the number of well-
controlled studies on the potential toxicities 
of nanosilver as well as the current knowledge 
of the kinetics of nanosilver is too limited to 
provide a proper foundation of human risk 
assessment. The SCENIHR is also likely to 
note that nanosilver has been found to be 
absorbed and distributed to target organs 
(such as the liver, lungs and olfactory bulb), 
and to have caused inflammation and liver 
damage in rodents after oral exposure. And 
increases in the production of reactive oxygen 
species in vitro10,14,16,19,20,26 will probably be 
mentioned as well.
On the environmental toxicity front, the 
SCENIHR is likely to state something very 
general about it being well known that both 
bulk silver and nanosilver are potentially toxic 
to the environment with the concentration 
that causes an adverse effect in 50% of a 
population being in the lower parts-per-
billion range for aquatic organisms3,20,23,26. 
Moreover, because inhibition of nitrifying 
bacteria by nanosilver has been observed 
in the very few original studies that have 
been published, the SCENIHR will have 
to consider this topic under the heading 
of ‘Other environmental, health and safety 
(EHS) issues’ because this phenomenon 
might affect the proper functioning of 
wastewater treatment plants20,23,26. It remains 
uncertain whether nanosilver is more toxic 
than ionic silver, the report is likely to say, 
because the effects seen in many cases can be 
ascribed to ionic silver: however, some studies 
have documented a more pronounced effect 
associated with nanosilver, but the data is 
inconclusive2,9,19,22,24,25.
Because there have been very few original 
studies of the relationship between nanosilver 
and the development of antimicrobial 
resistance (less than five to the best of our 
knowledge), it is likely that the SCENIHR will 
rely heavily on the seven review articles that 
have addressed this topic3,7,10,15,17,19,25. Evidence 
that the increasing use of nanosilver may 
be leading to bacterial and fungal resistance 
towards silver include reports of resistance 
to silver-based burn dressings (originally 
published in the mid-1970s and reviewed 
Many of these reviews and 
reports go through the same 
literature, cover the same 
ground and identify many 
of the same data gaps and 
research needs.
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in refs 3,7)28,29 and the finding that 10% of 
the intestinal bacteria tested randomly in a 
Chicago hospital had genes that are resistant 
to silver ions (originally published in 2003 
and reviewed in ref. 17)30. However, citing 
a leading article31 that was published in the 
Journal of Antimicrobial Chemotherapy in 
2007, the reviews collectively conclude that 
further studies on antimicrobial resistance 
are needed because there are currently 
no standardized methods for testing the 
antimicrobial activity of silver. (This is 
partly because the solubility of nanosilver 
is not fully understood, and the solubility 
influences the bioavailability which, in turn, 
influences the sensitivity of silver-resistant 
and silver-sensitive bacteria17.) Finally, we 
predict that the SCENIHR will underline 
the importance of silver speciation as this 
has been a general theme in many previous 
reviews3,11,14,16,18–20,24–26.
The SCENIHR review is due to come out 
in early 2013. Although the committee can 
call on additional expertise from outside 
experts within the specific subject, one 
permanent committee member often acts 
as a rapporteur and prepares a draft opinion 
that is voted on. Given the many high-profile 
reviews already available, we find it unlikely 
that the scientific committee will reach 
any significant new insights. One wonders, 
therefore, why the European Commission has 
asked for yet another review on this topic.
No regulatory action has so far been taken 
to limit human and environmental exposure 
of nanosilver. Although it may be common 
practice for regulators to ask for ‘their own 
review’ from a scientific advisory group, 
rather than acting on reviews published 
as scientific papers, it seems that many of 
these reviews have been commissioned 
by regulators with a purpose of delaying 
decisions on regulatory measures that 
should be implemented. It would not be the 
first time that regulators are ‘buying time’ 
before making difficult decisions that will be 
against the interests of certain stakeholders32. 
Although it is clear that the SCENIHR 
cannot decline requests from the European 
Commission for scientific opinions, it seems 
that the committee is being used by the 
Commission to stall the regulatory decision-
making process until 2013. By initiating 
one review after the other, regulators have 
created an unfortunate situation of ‘paralysis 
by analysis’ because reviews tend to identify 
additional research needs rather than the 
options for optimal regulatory policies.
We acknowledge that answering the 
question of how to regulate the use of 
nanosilver is not easy given the different 
views of the different stakeholders in this 
debate and the complex regulatory landscape 
associated with the many applications 
of nanosilver. However, some of the 
reviews already published offer plenty of 
recommendations on actions that could be 
taken. Back in 2008, for example, Luoma3 
Table 1 | Many of the reviews on nanosilver that have been published since 2008 (first column) have already addressed the four 
questions on the environmental, health and safety (EHS) aspects of nanosilver that the SCENIHR was recently asked to review. Page 
numbers for the part(s) of each review that are relevant to these questions are listed in columns 2–5.
Reference Human health and the 
environmental  implications?
Increase in selection of silver-
resistant microorganisms?
Reduction in  the efficacy  
of nanosilver?
Other EHS 
issues?
Chen and Schluesener2 1–12 27
Luoma3 25–35
Panyala et  al.4 119–124
Sharma et  al.5 93–94 89–93
DEFRA (UK)6 71, 73, 80, 97–100, 139, 142, 145 97
BfR (Germany)7 3–6
RIVM (Netherlands)8 29–41
Rai et  al.9 82 77–81
Wijnhoven et  al.10 111–114, 121–131 116 115–116
Ahamed et  al.11 1842–1846
Cao and Liu12 673–674
Chaloupka et  al.13 585 581–585
Christensen et  al. 14 286–294
Duran et  al.15 954–956 951–952 952–954
Johnston et  al.16 330–342
Marambio-Jones and Hoek17 1539, 1543–154 1531–1538 1542–1543
Quadros and Marr18 776–779
EPA (US)19 98–133 19–20, 74 134–146
JRC (EC)20 121–137, 212–217, 305–325
Fabrega et  al.21 518–529 527–528
Gangwal et  al.22 1539–1546
Musee et  al.23 1169–1174 1179
Nowack et  al.24 1180–1182
Stensberg et  al.25 880–882 881
Danish EPA26 74–88
By initiating one review 
after the other, regulators 
have created an unfortunate 
situation of ‘paralysis 
by  analysis’.
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sketched out a multi-faceted strategy that 
included: (1) the development of clear rules 
defining the ingredients of a product using 
the unique physical and chemical attributes 
of the ingredients to track production, use 
and environmental release/dispersal data; (2) 
the assessment of what information is needed 
to oversee safe use of nanosilver; (3) the 
evaluation of the relevance and shortcomings 
of current silver-relevant regulations. In 
2009, DEFRA in the UK recommended the 
application of the precautionary principle6, 
whereas the BfR in Germany urged producers 
not to use nanosilver in foods and everyday 
products7. However, little progress has 
been made in implementing any of these 
recommendations.
Arguably, we all want that the pros and 
cons of regulatory policy options be based 
on the best available science while taking 
broader socio-economical and ethical 
aspects into consideration before deciding 
on the appropriate regulatory measures 
concerning human and environmental 
exposure to nanosilver. Although it is 
common for independent scientific experts 
to be commissioned to gather, analyse and 
review the available scientific information, 
and to provide recommendations on how 
to address a given risk, we do not see the 
need for further reviews. It is time for the 
European Commission to decide on the 
regulatory measures that are appropriate 
for nanosilver. These measures should then 
be implemented wholeheartedly and their 
effectiveness monitored. ❐
Steffen Foss Hansen* and Anders Baun are in 
the Department of Environmental Engineering, 
Technical University of Denmark, 2800 
Lyngby, Denmark.  
*e-mail: sfh@env.dtu.dk
References
1. http://ec.europa.eu/health/scientific_committees/emerging/docs/
scenihr_q_027.pdf
2. Chen, X. & Schluesener, H. J. Toxicol. Lett. 176, 1–12 (2008).
3. Luoma, S. http://www.nanotechproject.org/process/assets/
files/7036/nano_pen_15_final.pdf (2008).
4. Panyala, N. R. et al. J. Appl. Biomed. 6, 117–129 (2008).
5. Sharma, V. K. et al. Adv. Colloid Interface Sci. 145, 83–96 (2009).
6. DEFRA; http://go.nature.com/seP6xK (2009).
7. BfR; http://go.nature.com/5e2Qnc (2009).
8. RIVM; http://go.nature.com/bta72t (2009).
9. Rai, M. et al. Biotechnol. Adv. 27, 76–83 (2009).
10. Wijnhoven, S. W. P. et al. Nanotoxicol. 3, 109–138 (2009).
11. Ahamed, M. et al. Clin. Chim. Acta 411, 1841–1848 (2010).
12. Cao, H. & Liu, X. Wiley Interdisciplinary Rev. Nanomed
 Nanobiotechnol. 2, 670–684 (2010).
13. Chaloupka, K. et al. Trends Biotechnol. 28, 580–588 (2010).
14. Christensen, F. M. et al. Nanotoxicol. 4, 284–295 (2010).
15. Duran, N. et al. J. Brazilian Chem. Soc. 21, 949–959 (2010).
16. Johnston, H. J. et al. Critical Rev. Toxicol. 40, 328–346 (2010).
17. Marambio-Jones, C. & Hoek, E. M. V. J. Nanoparticle Res.  
12, 1531–1551 (2010).
18. Quadros, M. E. & Marr, L. C. J. Air Waste Manage. Assoc.  
60, 770–781 (2010).
19. EPA; http://www.epa.gov/nanoscience/files/ 
NanoPaper1.pdf (2010).
20. JRC; http://ihcp.jrc.ec.europa.eu/whats-new/ 
enhres-final-report (2010).
21. Fabrega, J. et al. Environ. Intl 37, 517–531 (2011).
22. Gangwal, S. et al. Environ. Health Perspect. 119, 1539–1546 (2011).
23. Musee, N. et al. J. Environ. Monitoring 13, 1164–1183 (2011).
24. Nowack, B. et al. Environ. Sci. Technol. 45, 1177–1183 (2011).
25. Stensberg, M. C. et al. Nanomedicine 6, 879–898 (2011).
26. Danish EPA; http://go.nature.com/qQsSDP (2011).
27. http://www.nanotechproject.org/inventories/consumer/ 
browse/products
28. McHugh, G. L. et al. The Lancet 305, 235–240 (1975).
29. Annear, D. I. et al. J. Clin. Pathol. 29, 441–443 (1976).
30. Silver, S. FEMS Microbiol. Rev. 27, 341–353 (2003).
31. Chopra, I. J. Antimicrob. Chemother. 59, 587–590 (2007).
32. European Environment Agency; http://www.eea.europa.eu/
publications/environmental_issue_report_2001_22 (2002).
Published online: 1 July 2012
© 2012 Macmillan Publishers Limited. All rights reserved
